Capital Advisors Ltd. LLC Purchases 54 Shares of Eli Lilly and Company (NYSE:LLY)

Capital Advisors Ltd. LLC grew its position in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 9.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 597 shares of the company’s stock after acquiring an additional 54 shares during the period. Capital Advisors Ltd. LLC’s holdings in Eli Lilly and were worth $165,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of LLY. Two Sigma Advisers LP raised its stake in shares of Eli Lilly and by 6,719.9% during the third quarter. Two Sigma Advisers LP now owns 2,025,500 shares of the company’s stock valued at $467,992,000 after acquiring an additional 1,995,800 shares during the last quarter. Capital World Investors raised its stake in shares of Eli Lilly and by 9.8% during the third quarter. Capital World Investors now owns 16,790,382 shares of the company’s stock valued at $3,879,410,000 after acquiring an additional 1,502,363 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Eli Lilly and by 1,509.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,054,479 shares of the company’s stock valued at $243,637,000 after acquiring an additional 988,944 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Eli Lilly and by 1,123.5% during the third quarter. Renaissance Technologies LLC now owns 1,053,447 shares of the company’s stock valued at $243,399,000 after acquiring an additional 967,347 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in shares of Eli Lilly and by 10.7% during the third quarter. Jennison Associates LLC now owns 9,864,516 shares of the company’s stock valued at $2,279,196,000 after acquiring an additional 953,521 shares during the last quarter. 82.16% of the stock is owned by hedge funds and other institutional investors.

Several brokerages recently issued reports on LLY. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and from $234.00 to $264.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Mizuho reduced their price target on shares of Eli Lilly and from $302.00 to $293.00 and set a “buy” rating on the stock in a research report on Friday, February 4th. Sanford C. Bernstein boosted their price target on shares of Eli Lilly and from $250.00 to $300.00 and gave the company a “market perform” rating in a research report on Monday, January 3rd. Wells Fargo & Company boosted their price target on shares of Eli Lilly and from $280.00 to $305.00 in a research report on Friday. Finally, StockNews.com cut shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research report on Saturday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $299.06.

In other news, CAO Donald A. Zakrowski sold 1,660 shares of Eli Lilly and stock in a transaction on Friday, February 25th. The shares were sold at an average price of $243.84, for a total transaction of $404,774.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Ilya Yuffa sold 1,000 shares of Eli Lilly and stock in a transaction on Tuesday, February 15th. The stock was sold at an average price of $237.45, for a total transaction of $237,450.00. The disclosure for this sale can be found here. Insiders sold 1,088,551 shares of company stock worth $307,943,730 in the last 90 days. 0.12% of the stock is currently owned by corporate insiders.

Shares of LLY traded down $5.14 on Friday, hitting $292.13. 3,910,872 shares of the stock traded hands, compared to its average volume of 2,576,194. The company has a market capitalization of $278.21 billion, a PE ratio of 43.28, a P/E/G ratio of 2.14 and a beta of 0.43. The company has a debt-to-equity ratio of 1.68, a quick ratio of 0.97 and a current ratio of 1.23. The business has a 50 day simple moving average of $281.25 and a 200 day simple moving average of $262.96. Eli Lilly and Company has a one year low of $181.19 and a one year high of $314.00.

Eli Lilly and (NYSE:LLYGet Rating) last announced its quarterly earnings results on Thursday, April 28th. The company reported $2.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.32 by $0.30. The company had revenue of $7.81 billion during the quarter, compared to the consensus estimate of $7.29 billion. Eli Lilly and had a net margin of 19.71% and a return on equity of 96.36%. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.87 earnings per share. On average, equities analysts expect that Eli Lilly and Company will post 8.24 earnings per share for the current year.

Eli Lilly and Company Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.